Madrigal's lead therapy is driving 127% year-over-year revenue growth — the highest rate in its industry cohort — and the risk/reward of approximately 2.6-to-1 remains favorable with 18% upside to the consensus target, but two consecutive earnings misses before the most recent quarter, a 20% short interest, and single-product dependency require evidence of sustained execution before the setup becomes fully compelling.
Thesis pillars
- Earnings Execution Inconsistency↑Improving
- Industry Leading Revenue Acceleration→Stable
- Single Product Regulatory Concentration↑Improving
- +1 more pillar — see the Why tab for full reasoning
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Multiple concerning factors at $541.19: Concentration risk — Product: Rezdiffra; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2).
Madrigal Pharmaceuticals is a biopharmaceutical company whose sole commercialized product, Rezdiffra (resmetirom), received FDA accelerated approval in March 2024 as the first therapy for noncirrhotic MASH with moderate-to-advanced liver fibrosis. Rezdiffra generated $958.4... Read more
Sell if holding. Multiple concerning factors at $541.19: Concentration risk — Product: Rezdiffra; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2). Chart setup: Golden cross, above all MAs, RSI 58, MACD bullish. Score 5.9/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 61d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Madrigal Pharmaceuticals, Inc.
About Madrigal Pharmaceuticals, Inc.
Rezdiffra (resmetirom), the first FDA-approved therapy for MASH, generated $958.4 million in net product revenue for Madrigal Pharmaceuticals in 2025, its first full calendar year of U.S. sales following the April 2024 commercial launch. Quarterly sales annualized at greater than $1.0 billion as of December 31, 2025. The European Commission granted a conditional marketing authorization in August 2025, and the company launched Rezdiffra in Germany in September 2025 — making it the first medication approved by both the FDA and EC for noncirrhotic MASH with moderate to advanced liver fibrosis (F2–F3).
Madrigal generates revenue entirely from prescriptions of Rezdiffra, a once-daily oral thyroid hormone receptor beta agonist. In the United States, the company sells through specialty pharmacy channels and has secured broad first-line formulary access across commercial payers. The company targets 315,000 identified U.S. MASH patients with F2–F3 fibrosis under specialist care as of 2023 market data, with the number of patients under specialist care estimated to have grown nearly 50% through 2025. Beyond Germany, country-by-country EU launches depend on completion of national reimbursement procedures. A U.S. patent listed in the FDA Orange Book covers Rezdiffra's commercial dosing regimen through February 2045, providing a long exclusivity runway. No competing MASH product is approved as of the filing date.
Show full overview
Rezdiffra's FDA approval is conditional under the Subpart H accelerated approval pathway, requiring confirmatory post-marketing studies. The MAESTRO-NASH trial (54-month outcomes, results expected 2028) must demonstrate hepatic clinical endpoint benefit to maintain the noncirrhotic MASH approval; the Phase 3 MAESTRO-NASH OUTCOMES trial (fully enrolled, results expected 2027) targets label expansion to compensated MASH cirrhosis (F4c). Failure to meet post-marketing commitments could trigger expedited withdrawal procedures under FDORA, and the EC's conditional marketing authorization must be renewed annually until converted to a standard authorization based on confirmatory data.
See also: Healthcare · Biotechnology
From Madrigal Pharmaceuticals, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-09-04Recent Developments — Madrigal Pharmaceuticals, Inc.
Latest news
- NEWS MDGL Maintained by Canaccord Genuity -- Price Target Raised to $587 - GuruFocus — GuruFocus positive
- NEWS Madrigal Pharmaceuticals Inc (MDGL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey — TradingKey negative
- NEWS Madrigal (MDGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance — Yahoo Finance positive
- NEWS Madrigal Pharmaceuticals (MDGL) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat — MarketBeat neutral
- NEWS MDGL stock surges most in a month on Eli Lilly buyout speculation - MSN — MSN positive
Generated 2026-09-04T19:02:09Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductRezdiffra10-K Item 1A: 'Our prospects are highly dependent on the success of our only approved product, Rezdiffra'
Material Events(8-K, last 90d)
- 2026-04-28Item 5.02LOWJulian C. Baker and Daniel J. Brennan reclassified from Class III and Class II to Class I directors on April 22, 2026, via simultaneous resignation and reappointment, solely to rebalance board class sizes before the 2026 Annual Meeting. No effective departure or new appointment.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $541.19: Concentration risk — Product: Rezdiffra; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2). Chart setup: Golden cross, above all MAs, RSI 58, MACD bullish. Prior stop was $506.16. Score 5.9/10, moderate confidence.
Take-profit target: $610.26 (+12.7% upside). Prior stop was $506.16. Stop-loss: $506.16.
Concentration risk — Product: Rezdiffra; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Consecutive earnings misses (2).
Madrigal Pharmaceuticals, Inc. trades at a P/E of N/A (forward 56.4). TrendMatrix value score: 5.0/10. Verdict: Sell.
24 analysts cover MDGL with a consensus score of 4.2/5. Average price target: $678.
What does Madrigal Pharmaceuticals, Inc. do?Madrigal Pharmaceuticals is a biopharmaceutical company whose sole commercialized product, Rezdiffra (resmetirom),...
Madrigal Pharmaceuticals is a biopharmaceutical company whose sole commercialized product, Rezdiffra (resmetirom), received FDA accelerated approval in March 2024 as the first therapy for noncirrhotic MASH with moderate-to-advanced liver fibrosis. Rezdiffra generated $958.4 million in net product revenue in 2025; the European Commission granted conditional marketing authorization in August 2025 and Germany launched in September 2025.